NASDAQ
1.47USD
-0.01 (-0.68%)
Dots are scored news catalysts — size = impact, color = sentiment. Tap one to read it.
Market cap
133.6M
P/E
—
EPS
—
Beta
2.50
52W range
0.96-3.87
Day range
1.46–1.50
Open
1.49
Prev close
1.48
Volume
749K
Avg volume
1.1M
Dividend
0.00
IPO
2010-04-22
https://seekingalpha.com/article/4925671-codexis-stock-eco-synthesis-and-runway-reset-warrant-rating-upgrade · 7/26/2026+0.40
https://www.globenewswire.com/news-release/2026/07/24/3332687/24825/en/Codexis-Announces-Pricing-of-Public-Offering-of-Common-Stock.html · 7/24/2026-0.20
https://www.zacks.com/stock/news/2882619/codexis-cdxs-beats-q4-earnings-and-revenue-estimates?cid=CS-STOCKNEWSAPI-FT-tale_of_the_tape|yseop_template_4-2882619 · 3/11/2026+0.60
https://www.globenewswire.com/news-release/2026/02/10/3235366/24825/en/Codexis-Achieves-ISO-9001-2015-Certification.html · 2/10/2026+0.60
https://seekingalpha.com/article/4840530-codexis-inc-cdxs-q3-2025-earnings-call-transcript · 11/7/2025+0.00
https://www.zacks.com/stock/news/2708917/codexis-cdxs-reports-q2-loss-tops-revenue-estimates?cid=CS-STOCKNEWSAPI-FT-tale_of_the_tape|yseop_template_4-2708917 · 8/13/2025+0.20
https://www.globenewswire.com/news-release/2025/08/13/3132965/24825/en/Codexis-Reports-Second-Quarter-2025-Financial-Results.html · 8/13/2025+0.80
Codexis, Inc. is a biotechnology firm dedicated to the discovery, development, and commercialization of enzymes and other protein-based solutions. Its diverse portfolio encompasses advanced biocatalyst products and related services, specialized chemical intermediates vital for subsequent processing steps, and proprietary biocatalyst panels and kits that empower clients to conduct effective chemistry screening. The company also extends its expertise through biocatalyst screening and sophisticated protein engineering services. Central to its operations is the proprietary CodeEvolver protein engineering technology platform. This innovative platform is instrumental in crafting and delivering high-performance biocatalysts capable of driving chemical transformations, thereby significantly enhancing the efficiency and productivity of manufacturing processes. Beyond industrial applications, the CodeEvolver platform is also leveraged for identifying novel biotherapeutic drug candidates for targeted human diseases, as well as for developing enzymes essential for molecular biology research and in vitro diagnostic applications. Primarily serving pharmaceutical manufacturers, Codexis distributes its products through its dedicated direct sales and business development teams across the United States and Europe. Established in 2002, the company maintains its headquarters in Redwood City, California.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works